
<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://proteopedia.org/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Disha+Sonwani</id>
	<title>Proteopedia - User contributions [en]</title>
	<link rel="self" type="application/atom+xml" href="https://proteopedia.org/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Disha+Sonwani"/>
	<link rel="alternate" type="text/html" href="https://proteopedia.org/Special:Contributions/Disha_Sonwani"/>
	<updated>2026-10-10T21:23:17Z</updated>
	<subtitle>User contributions</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://proteopedia.org/index.php?title=STING_Polymer_Structure_Reveals_Mechanisms_for_Activation,_Hyperactivation,_and_Inhibition_(Bi3323)&amp;diff=4396850</id>
		<title>STING Polymer Structure Reveals Mechanisms for Activation, Hyperactivation, and Inhibition (Bi3323)</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=STING_Polymer_Structure_Reveals_Mechanisms_for_Activation,_Hyperactivation,_and_Inhibition_(Bi3323)&amp;diff=4396850"/>
		<updated>2025-11-30T18:21:55Z</updated>

		<summary type="html">&lt;p&gt;Disha Sonwani: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==STING Polymer Structure Reveals Mechanisms for&lt;br /&gt;
Activation, Hyperactivation, and Inhibition==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;4F5W&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
The 4F5W structure represents human STING in its apo (ligand-free) open conformation.&lt;br /&gt;
In this state, the STING dimer is open, the C-terminal tail (CTT) remains locked, and the polymerization interface is hidden.&lt;br /&gt;
&lt;br /&gt;
STING is a key immune protein that becomes active when it binds the signaling molecule cGAMP. In its resting form, STING remains open and unable to signal; ligand binding shifts it into a closed, active state, allowing it to recruit downstream partners and trigger interferon production. This balance is crucial because inappropriate activation of STING can lead to severe autoimmune and inflammatory diseases, while insufficient activation weakens antiviral and anticancer immunity.&lt;br /&gt;
&lt;br /&gt;
The apo structure captured in this model represents STING in its natural, inactive condition. It provides the essential reference needed to understand how disease-causing mutations disrupt normal control, how ligand binding drives activation, and how different molecules can either stimulate or inhibit the pathway. This makes the structure valuable not only for understanding STING biology, but also for developing therapeutics that target this pathway in cancer, infection, and autoimmune disorders.&lt;br /&gt;
&lt;br /&gt;
== Function ==STING is a key sensor in our innate immune system. It does not detect DNA directly—instead, when DNA appears in the cytosol, the enzyme cGAS produces a signaling molecule called 2&#039;3&#039;-cGAMP. This cGAMP then binds to STING, triggering its activation.&lt;br /&gt;
&lt;br /&gt;
Once cGAMP binds, several structural changes occur:&lt;br /&gt;
&lt;br /&gt;
The STING dimer closes, shifting from its open resting shape.&lt;br /&gt;
&lt;br /&gt;
The C-terminal tail is released, which is normally tucked away in the inactive state.&lt;br /&gt;
&lt;br /&gt;
This release introduces a polymerization interface, enabling STING molecules to form higher-order structures.&lt;br /&gt;
&lt;br /&gt;
STING then recruits TBK1, leading to the activation of IRF3 and the production of type I interferons, which drive antiviral and anticancer immune responses.&lt;br /&gt;
&lt;br /&gt;
The 4F5W structure captures STING in an open, inactive conformation that is unable to initiate signaling before any of these steps occur.&lt;br /&gt;
&lt;br /&gt;
== Disease == Proper control of STING activity is essential for immune balance. When STING becomes overactive, the body produces too much interferon, which can drive several autoimmune and inflammatory diseases. Examples include:&lt;br /&gt;
&lt;br /&gt;
SAVI (STING-associated vasculopathy with onset in infancy)&lt;br /&gt;
&lt;br /&gt;
Systemic lupus erythematosus&lt;br /&gt;
&lt;br /&gt;
Multiple sclerosis&lt;br /&gt;
&lt;br /&gt;
Aicardi–Goutières syndrome&lt;br /&gt;
&lt;br /&gt;
Certain mutations such as R284S, V147L, and N154S disrupt normal regulation. These mutations can cause the C-terminal tail to come loose even without ligand, pushing STING into a closed, activated-like conformation. As a result, STING forms polymers spontaneously and continuously signals, leading to chronic inflammation.&lt;br /&gt;
&lt;br /&gt;
On the other hand, loss-of-function mutations weaken STING signaling. This results in:&lt;br /&gt;
&lt;br /&gt;
Increased susceptibility to viral infections&lt;br /&gt;
&lt;br /&gt;
A reduced anti-tumor immune response&lt;br /&gt;
&lt;br /&gt;
The apo 4F5W structure represents the healthy, inactive “open” form of STING. It serves as an important reference for understanding how disease-causing mutations shift STING from a normal resting state into an uncontrolled, hyperactive one.&lt;br /&gt;
&lt;br /&gt;
== Relevance == The 4F5W structure is valuable because it captures STING in its true resting, inactive state. This open apo form serves as the baseline against which all ligand-bound and mutated versions of STING are compared.&lt;br /&gt;
&lt;br /&gt;
By having this reference structure, researchers can clearly see how STING changes when different molecules bind:&lt;br /&gt;
&lt;br /&gt;
Apo STING → open and inactive&lt;br /&gt;
&lt;br /&gt;
CDA-bound STING → closed conformation&lt;br /&gt;
&lt;br /&gt;
cGAMP-bound STING → even more tightly closed, fully activated state&lt;br /&gt;
&lt;br /&gt;
These comparisons explain why ligand binding is essential for STING activation and how the structural shift from open to closed directly triggers downstream immune signaling.&lt;br /&gt;
&lt;br /&gt;
Because of this, 4F5W plays an important role in drug development. It helps guide the design of:&lt;br /&gt;
&lt;br /&gt;
STING agonists, which strengthen immune responses for cancer immunotherapy&lt;br /&gt;
&lt;br /&gt;
STING inhibitors, which can calm down excessive signaling in autoimmune and inflammatory diseases&lt;br /&gt;
&lt;br /&gt;
In short, 4F5W provides the structural foundation needed to understand, compare, and therapeutically target the STING pathway.&lt;br /&gt;
&lt;br /&gt;
== Structural highlights == Open dimer conformation (47–54 Å)&lt;br /&gt;
In the 4F5W apo structure, the two α2 helices are positioned far apart, creating a wide, open dimer.&lt;br /&gt;
This open arrangement corresponds to the inactive form of STING and matches the purple structure shown in your image.&lt;br /&gt;
&lt;br /&gt;
Ligand binding drives dimer closure (34–35 Å)&lt;br /&gt;
When a ligand such as cyclic-di-AMP binds, the dimer shifts into a much tighter, closed conformation.&lt;br /&gt;
The gold structure in your image clearly demonstrates this ligand-induced closing movement.&lt;br /&gt;
&lt;br /&gt;
C-terminal tail (CTT) is locked down in the apo state&lt;br /&gt;
In 4F5W, the C-terminal tail remains securely tucked into the protein.&lt;br /&gt;
This prevents:&lt;br /&gt;
&lt;br /&gt;
TBK1 from binding&lt;br /&gt;
&lt;br /&gt;
Any downstream signaling&lt;br /&gt;
&lt;br /&gt;
Any formation of STING polymers&lt;br /&gt;
&lt;br /&gt;
The polymerization interface is hidden&lt;br /&gt;
Because the CTT is still in place, the surface needed for polymer formation is not exposed in the apo structure.&lt;br /&gt;
Only after ligand binding—when the tail is released—does STING reveal this interface and form Cys148-linked polymers.&lt;br /&gt;
&lt;br /&gt;
Apo STING is unable to polymerize&lt;br /&gt;
Unlike ligand-bound structures (cGAMP- or CDA-bound STING), the apo 4F5W conformation cannot form linear polymers on the ER membrane.&lt;br /&gt;
This inability to polymerize explains why the apo form remains fully inactive.&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References == Ergun, S. L., Fernandez, D., Weiss, T. M., &amp;amp; Li, L. (2019). STING polymer structure reveals mechanisms for activation, hyperactivation, and inhibition. Cell, 178, 290–301&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Disha Sonwani</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=File:4F5W.pse&amp;diff=4396806</id>
		<title>File:4F5W.pse</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=File:4F5W.pse&amp;diff=4396806"/>
		<updated>2025-11-30T17:50:54Z</updated>

		<summary type="html">&lt;p&gt;Disha Sonwani: uploaded a new version of &amp;quot;Image:4F5W.pse&amp;quot;&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;The 4F5W structure captures STING in its calm, inactive state. In this form, the protein sits as an open dimer, with the two arms of the molecule gently spread apart. Because no ligand is bound, STING isn’t under any pressure to change shape—so it stays relaxed. The C-terminal tail remains neatly tucked away, almost like a safety lock that keeps the protein from accidentally activating.&lt;br /&gt;
&lt;br /&gt;
This structure represents STING exactly as it looks before sensing any danger, making it the perfect reference for understanding how the protein later closes, shifts, and comes alive when cGAMP or other ligands bind.&lt;/div&gt;</summary>
		<author><name>Disha Sonwani</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=File:4F5W_2.pse&amp;diff=4396804</id>
		<title>File:4F5W 2.pse</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=File:4F5W_2.pse&amp;diff=4396804"/>
		<updated>2025-11-30T17:50:25Z</updated>

		<summary type="html">&lt;p&gt;Disha Sonwani: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&lt;/div&gt;</summary>
		<author><name>Disha Sonwani</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=STING_Polymer_Structure_Reveals_Mechanisms_for_Activation,_Hyperactivation,_and_Inhibition_(Bi3323)&amp;diff=4396775</id>
		<title>STING Polymer Structure Reveals Mechanisms for Activation, Hyperactivation, and Inhibition (Bi3323)</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=STING_Polymer_Structure_Reveals_Mechanisms_for_Activation,_Hyperactivation,_and_Inhibition_(Bi3323)&amp;diff=4396775"/>
		<updated>2025-11-30T17:37:32Z</updated>

		<summary type="html">&lt;p&gt;Disha Sonwani: I made mistake with loading PDB&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==STING Polymer Structure Reveals Mechanisms for&lt;br /&gt;
Activation, Hyperactivation, and Inhibition==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;4F5W&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
The 4F5W structure represents human STING in its apo (ligand-free) open conformation.&lt;br /&gt;
In this state, the STING dimer is open, the C-terminal tail (CTT) remains locked, and the polymerization interface is hidden.&lt;br /&gt;
&lt;br /&gt;
STING is a key immune protein that becomes active when it binds the signaling molecule cGAMP. In its resting form, STING remains open and unable to signal; ligand binding shifts it into a closed, active state, allowing it to recruit downstream partners and trigger interferon production. This balance is crucial because inappropriate activation of STING can lead to severe autoimmune and inflammatory diseases, while insufficient activation weakens antiviral and anticancer immunity.&lt;br /&gt;
&lt;br /&gt;
The apo structure captured in this model represents STING in its natural, inactive condition. It provides the essential reference needed to understand how disease-causing mutations disrupt normal control, how ligand binding drives activation, and how different molecules can either stimulate or inhibit the pathway. This makes the structure valuable not only for understanding STING biology, but also for developing therapeutics that target this pathway in cancer, infection, and autoimmune disorders.&lt;br /&gt;
&lt;br /&gt;
== Function ==STING is a key sensor in our innate immune system. It does not detect DNA directly—instead, when DNA appears in the cytosol, the enzyme cGAS produces a signaling molecule called 2&#039;3&#039;-cGAMP. This cGAMP then binds to STING, triggering its activation.&lt;br /&gt;
&lt;br /&gt;
Once cGAMP binds, several structural changes occur:&lt;br /&gt;
&lt;br /&gt;
The STING dimer closes, shifting from its open resting shape.&lt;br /&gt;
&lt;br /&gt;
The C-terminal tail is released, which is normally tucked away in the inactive state.&lt;br /&gt;
&lt;br /&gt;
This release introduces a polymerization interface, enabling STING molecules to form higher-order structures.&lt;br /&gt;
&lt;br /&gt;
STING then recruits TBK1, leading to the activation of IRF3 and the production of type I interferons, which drive antiviral and anticancer immune responses.&lt;br /&gt;
&lt;br /&gt;
The 4F5W structure captures STING in an open, inactive conformation that is unable to initiate signaling before any of these steps occur.&lt;br /&gt;
&lt;br /&gt;
== Disease == Proper control of STING activity is essential for immune balance. When STING becomes overactive, the body produces too much interferon, which can drive several autoimmune and inflammatory diseases. Examples include:&lt;br /&gt;
&lt;br /&gt;
SAVI (STING-associated vasculopathy with onset in infancy)&lt;br /&gt;
&lt;br /&gt;
Systemic lupus erythematosus&lt;br /&gt;
&lt;br /&gt;
Multiple sclerosis&lt;br /&gt;
&lt;br /&gt;
Aicardi–Goutières syndrome&lt;br /&gt;
&lt;br /&gt;
Certain mutations such as R284S, V147L, and N154S disrupt normal regulation. These mutations can cause the C-terminal tail to come loose even without ligand, pushing STING into a closed, activated-like conformation. As a result, STING forms polymers spontaneously and continuously signals, leading to chronic inflammation.&lt;br /&gt;
&lt;br /&gt;
On the other hand, loss-of-function mutations weaken STING signaling. This results in:&lt;br /&gt;
&lt;br /&gt;
Increased susceptibility to viral infections&lt;br /&gt;
&lt;br /&gt;
A reduced anti-tumor immune response&lt;br /&gt;
&lt;br /&gt;
The apo 4F5W structure represents the healthy, inactive “open” form of STING. It serves as an important reference for understanding how disease-causing mutations shift STING from a normal resting state into an uncontrolled, hyperactive one.&lt;br /&gt;
&lt;br /&gt;
== Relevance == The 4F5W structure is valuable because it captures STING in its true resting, inactive state. This open apo form serves as the baseline against which all ligand-bound and mutated versions of STING are compared.&lt;br /&gt;
&lt;br /&gt;
By having this reference structure, researchers can clearly see how STING changes when different molecules bind:&lt;br /&gt;
&lt;br /&gt;
Apo STING → open and inactive&lt;br /&gt;
&lt;br /&gt;
CDA-bound STING → closed conformation&lt;br /&gt;
&lt;br /&gt;
cGAMP-bound STING → even more tightly closed, fully activated state&lt;br /&gt;
&lt;br /&gt;
These comparisons explain why ligand binding is essential for STING activation and how the structural shift from open to closed directly triggers downstream immune signaling.&lt;br /&gt;
&lt;br /&gt;
Because of this, 4F5W plays an important role in drug development. It helps guide the design of:&lt;br /&gt;
&lt;br /&gt;
STING agonists, which strengthen immune responses for cancer immunotherapy&lt;br /&gt;
&lt;br /&gt;
STING inhibitors, which can calm down excessive signaling in autoimmune and inflammatory diseases&lt;br /&gt;
&lt;br /&gt;
In short, 4F5W provides the structural foundation needed to understand, compare, and therapeutically target the STING pathway.&lt;br /&gt;
&lt;br /&gt;
== Structural highlights == Open dimer conformation (47–54 Å)&lt;br /&gt;
In the 4F5W apo structure, the two α2 helices are positioned far apart, creating a wide, open dimer.&lt;br /&gt;
This open arrangement corresponds to the inactive form of STING and matches the purple structure shown in your image.&lt;br /&gt;
&lt;br /&gt;
Ligand binding drives dimer closure (34–35 Å)&lt;br /&gt;
When a ligand such as cyclic-di-AMP binds, the dimer shifts into a much tighter, closed conformation.&lt;br /&gt;
The gold structure in your image clearly demonstrates this ligand-induced closing movement.&lt;br /&gt;
&lt;br /&gt;
C-terminal tail (CTT) is locked down in the apo state&lt;br /&gt;
In 4F5W, the C-terminal tail remains securely tucked into the protein.&lt;br /&gt;
This prevents:&lt;br /&gt;
&lt;br /&gt;
TBK1 from binding&lt;br /&gt;
&lt;br /&gt;
Any downstream signaling&lt;br /&gt;
&lt;br /&gt;
Any formation of STING polymers&lt;br /&gt;
&lt;br /&gt;
The polymerization interface is hidden&lt;br /&gt;
Because the CTT is still in place, the surface needed for polymer formation is not exposed in the apo structure.&lt;br /&gt;
Only after ligand binding—when the tail is released—does STING reveal this interface and form Cys148-linked polymers.&lt;br /&gt;
&lt;br /&gt;
Apo STING is unable to polymerize&lt;br /&gt;
Unlike ligand-bound structures (cGAMP- or CDA-bound STING), the apo 4F5W conformation cannot form linear polymers on the ER membrane.&lt;br /&gt;
This inability to polymerize explains why the apo form remains fully inactive.&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Disha Sonwani</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=STING_Polymer_Structure_Reveals_Mechanisms_for_Activation,_Hyperactivation,_and_Inhibition_(Bi3323)&amp;diff=4396769</id>
		<title>STING Polymer Structure Reveals Mechanisms for Activation, Hyperactivation, and Inhibition (Bi3323)</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=STING_Polymer_Structure_Reveals_Mechanisms_for_Activation,_Hyperactivation,_and_Inhibition_(Bi3323)&amp;diff=4396769"/>
		<updated>2025-11-30T17:35:17Z</updated>

		<summary type="html">&lt;p&gt;Disha Sonwani: Revised the page to give clearer explanations of STING’s function, its role in disease, why this structure is relevant, and the key structural features of the apo form.&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==STING Polymer Structure Reveals Mechanisms for&lt;br /&gt;
Activation, Hyperactivation, and Inhibition==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;Bi3323&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
The 4F5W structure represents human STING in its apo (ligand-free) open conformation.&lt;br /&gt;
In this state, the STING dimer is open, the C-terminal tail (CTT) remains locked, and the polymerization interface is hidden.&lt;br /&gt;
&lt;br /&gt;
STING is a key immune protein that becomes active when it binds the signaling molecule cGAMP. In its resting form, STING remains open and unable to signal; ligand binding shifts it into a closed, active state, allowing it to recruit downstream partners and trigger interferon production. This balance is crucial because inappropriate activation of STING can lead to severe autoimmune and inflammatory diseases, while insufficient activation weakens antiviral and anticancer immunity.&lt;br /&gt;
&lt;br /&gt;
The apo structure captured in this model represents STING in its natural, inactive condition. It provides the essential reference needed to understand how disease-causing mutations disrupt normal control, how ligand binding drives activation, and how different molecules can either stimulate or inhibit the pathway. This makes the structure valuable not only for understanding STING biology, but also for developing therapeutics that target this pathway in cancer, infection, and autoimmune disorders.&lt;br /&gt;
&lt;br /&gt;
== Function ==STING is a key sensor in our innate immune system. It does not detect DNA directly—instead, when DNA appears in the cytosol, the enzyme cGAS produces a signaling molecule called 2&#039;3&#039;-cGAMP. This cGAMP then binds to STING, triggering its activation.&lt;br /&gt;
&lt;br /&gt;
Once cGAMP binds, several structural changes occur:&lt;br /&gt;
&lt;br /&gt;
The STING dimer closes, shifting from its open resting shape.&lt;br /&gt;
&lt;br /&gt;
The C-terminal tail is released, which is normally tucked away in the inactive state.&lt;br /&gt;
&lt;br /&gt;
This release introduces a polymerization interface, enabling STING molecules to form higher-order structures.&lt;br /&gt;
&lt;br /&gt;
STING then recruits TBK1, leading to the activation of IRF3 and the production of type I interferons, which drive antiviral and anticancer immune responses.&lt;br /&gt;
&lt;br /&gt;
The 4F5W structure captures STING in an open, inactive conformation that is unable to initiate signaling before any of these steps occur.&lt;br /&gt;
&lt;br /&gt;
== Disease == Proper control of STING activity is essential for immune balance. When STING becomes overactive, the body produces too much interferon, which can drive several autoimmune and inflammatory diseases. Examples include:&lt;br /&gt;
&lt;br /&gt;
SAVI (STING-associated vasculopathy with onset in infancy)&lt;br /&gt;
&lt;br /&gt;
Systemic lupus erythematosus&lt;br /&gt;
&lt;br /&gt;
Multiple sclerosis&lt;br /&gt;
&lt;br /&gt;
Aicardi–Goutières syndrome&lt;br /&gt;
&lt;br /&gt;
Certain mutations such as R284S, V147L, and N154S disrupt normal regulation. These mutations can cause the C-terminal tail to come loose even without ligand, pushing STING into a closed, activated-like conformation. As a result, STING forms polymers spontaneously and continuously signals, leading to chronic inflammation.&lt;br /&gt;
&lt;br /&gt;
On the other hand, loss-of-function mutations weaken STING signaling. This results in:&lt;br /&gt;
&lt;br /&gt;
Increased susceptibility to viral infections&lt;br /&gt;
&lt;br /&gt;
A reduced anti-tumor immune response&lt;br /&gt;
&lt;br /&gt;
The apo 4F5W structure represents the healthy, inactive “open” form of STING. It serves as an important reference for understanding how disease-causing mutations shift STING from a normal resting state into an uncontrolled, hyperactive one.&lt;br /&gt;
&lt;br /&gt;
== Relevance == The 4F5W structure is valuable because it captures STING in its true resting, inactive state. This open apo form serves as the baseline against which all ligand-bound and mutated versions of STING are compared.&lt;br /&gt;
&lt;br /&gt;
By having this reference structure, researchers can clearly see how STING changes when different molecules bind:&lt;br /&gt;
&lt;br /&gt;
Apo STING → open and inactive&lt;br /&gt;
&lt;br /&gt;
CDA-bound STING → closed conformation&lt;br /&gt;
&lt;br /&gt;
cGAMP-bound STING → even more tightly closed, fully activated state&lt;br /&gt;
&lt;br /&gt;
These comparisons explain why ligand binding is essential for STING activation and how the structural shift from open to closed directly triggers downstream immune signaling.&lt;br /&gt;
&lt;br /&gt;
Because of this, 4F5W plays an important role in drug development. It helps guide the design of:&lt;br /&gt;
&lt;br /&gt;
STING agonists, which strengthen immune responses for cancer immunotherapy&lt;br /&gt;
&lt;br /&gt;
STING inhibitors, which can calm down excessive signaling in autoimmune and inflammatory diseases&lt;br /&gt;
&lt;br /&gt;
In short, 4F5W provides the structural foundation needed to understand, compare, and therapeutically target the STING pathway.&lt;br /&gt;
&lt;br /&gt;
== Structural highlights == Open dimer conformation (47–54 Å)&lt;br /&gt;
In the 4F5W apo structure, the two α2 helices are positioned far apart, creating a wide, open dimer.&lt;br /&gt;
This open arrangement corresponds to the inactive form of STING and matches the purple structure shown in your image.&lt;br /&gt;
&lt;br /&gt;
Ligand binding drives dimer closure (34–35 Å)&lt;br /&gt;
When a ligand such as cyclic-di-AMP binds, the dimer shifts into a much tighter, closed conformation.&lt;br /&gt;
The gold structure in your image clearly demonstrates this ligand-induced closing movement.&lt;br /&gt;
&lt;br /&gt;
C-terminal tail (CTT) is locked down in the apo state&lt;br /&gt;
In 4F5W, the C-terminal tail remains securely tucked into the protein.&lt;br /&gt;
This prevents:&lt;br /&gt;
&lt;br /&gt;
TBK1 from binding&lt;br /&gt;
&lt;br /&gt;
Any downstream signaling&lt;br /&gt;
&lt;br /&gt;
Any formation of STING polymers&lt;br /&gt;
&lt;br /&gt;
The polymerization interface is hidden&lt;br /&gt;
Because the CTT is still in place, the surface needed for polymer formation is not exposed in the apo structure.&lt;br /&gt;
Only after ligand binding—when the tail is released—does STING reveal this interface and form Cys148-linked polymers.&lt;br /&gt;
&lt;br /&gt;
Apo STING is unable to polymerize&lt;br /&gt;
Unlike ligand-bound structures (cGAMP- or CDA-bound STING), the apo 4F5W conformation cannot form linear polymers on the ER membrane.&lt;br /&gt;
This inability to polymerize explains why the apo form remains fully inactive.&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Disha Sonwani</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=STING_Polymer_Structure_Reveals_Mechanisms_for_Activation,_Hyperactivation,_and_Inhibition_(Bi3323)&amp;diff=4396753</id>
		<title>STING Polymer Structure Reveals Mechanisms for Activation, Hyperactivation, and Inhibition (Bi3323)</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=STING_Polymer_Structure_Reveals_Mechanisms_for_Activation,_Hyperactivation,_and_Inhibition_(Bi3323)&amp;diff=4396753"/>
		<updated>2025-11-30T17:28:32Z</updated>

		<summary type="html">&lt;p&gt;Disha Sonwani: The STING protein plays a central role in the innate immune response by sensing cytosolic DNA through the second messenger 2’3’-cGAMP. The structure represented by PDB: 4F5W captures STING in its apo&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==STING Polymer Structure Reveals Mechanisms for&lt;br /&gt;
Activation, Hyperactivation, and Inhibition==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;Bi3323&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
The 4F5W structure represents human STING in its apo (ligand-free) open conformation.&lt;br /&gt;
In this state the STING dimer is open, the C-terminal tail (CTT) remains locked, and the polymerization interface is hidden.&lt;br /&gt;
&lt;br /&gt;
The image you uploaded shows:&lt;br /&gt;
&lt;br /&gt;
Purple = apo STING (open dimer)&lt;br /&gt;
&lt;br /&gt;
Gold = ligand-bound STING (cyclic-di-AMP)&lt;br /&gt;
&lt;br /&gt;
The overlay clearly shows how ligand binding closes the dimer compared to the open apo 4F5W structure.&lt;br /&gt;
&lt;br /&gt;
This open apo structure serves as the baseline for understanding how cGAMP, CDG, and CDA activate STING.&lt;br /&gt;
&lt;br /&gt;
== Function ==STING is a key sensor in our innate immune system. It does not detect DNA directly—instead, when DNA appears in the cytosol, the enzyme cGAS produces a signaling molecule called 2&#039;3&#039;-cGAMP. This cGAMP then binds to STING, triggering its activation.&lt;br /&gt;
&lt;br /&gt;
Once cGAMP binds, several structural changes occur:&lt;br /&gt;
&lt;br /&gt;
The STING dimer closes, shifting from its open resting shape.&lt;br /&gt;
&lt;br /&gt;
The C-terminal tail is released, which is normally tucked away in the inactive state.&lt;br /&gt;
&lt;br /&gt;
This release introduces a polymerization interface, enabling STING molecules to form higher-order structures.&lt;br /&gt;
&lt;br /&gt;
STING then recruits TBK1, leading to the activation of IRF3 and the production of type I interferons, which drive antiviral and anticancer immune responses.&lt;br /&gt;
&lt;br /&gt;
The 4F5W structure captures STING in an open, inactive conformation that is unable to initiate signaling before any of these steps occur.&lt;br /&gt;
&lt;br /&gt;
== Disease == Proper control of STING activity is essential for immune balance. When STING becomes overactive, the body produces too much interferon, which can drive several autoimmune and inflammatory diseases. Examples include:&lt;br /&gt;
&lt;br /&gt;
SAVI (STING-associated vasculopathy with onset in infancy)&lt;br /&gt;
&lt;br /&gt;
Systemic lupus erythematosus&lt;br /&gt;
&lt;br /&gt;
Multiple sclerosis&lt;br /&gt;
&lt;br /&gt;
Aicardi–Goutières syndrome&lt;br /&gt;
&lt;br /&gt;
Certain mutations such as R284S, V147L, and N154S disrupt normal regulation. These mutations can cause the C-terminal tail to come loose even without ligand, pushing STING into a closed, activated-like conformation. As a result, STING forms polymers spontaneously and continuously signals, leading to chronic inflammation.&lt;br /&gt;
&lt;br /&gt;
On the other hand, loss-of-function mutations weaken STING signaling. This results in:&lt;br /&gt;
&lt;br /&gt;
Increased susceptibility to viral infections&lt;br /&gt;
&lt;br /&gt;
A reduced anti-tumor immune response&lt;br /&gt;
&lt;br /&gt;
The apo 4F5W structure represents the healthy, inactive “open” form of STING. It serves as an important reference for understanding how disease-causing mutations shift STING from a normal resting state into an uncontrolled, hyperactive one.&lt;br /&gt;
&lt;br /&gt;
== Relevance == The 4F5W structure is valuable because it captures STING in its true resting, inactive state. This open apo form serves as the baseline against which all ligand-bound and mutated versions of STING are compared.&lt;br /&gt;
&lt;br /&gt;
By having this reference structure, researchers can clearly see how STING changes when different molecules bind:&lt;br /&gt;
&lt;br /&gt;
Apo STING → open and inactive&lt;br /&gt;
&lt;br /&gt;
CDA-bound STING → closed conformation&lt;br /&gt;
&lt;br /&gt;
cGAMP-bound STING → even more tightly closed, fully activated state&lt;br /&gt;
&lt;br /&gt;
These comparisons explain why ligand binding is essential for STING activation and how the structural shift from open to closed directly triggers downstream immune signaling.&lt;br /&gt;
&lt;br /&gt;
Because of this, 4F5W plays an important role in drug development. It helps guide the design of:&lt;br /&gt;
&lt;br /&gt;
STING agonists, which strengthen immune responses for cancer immunotherapy&lt;br /&gt;
&lt;br /&gt;
STING inhibitors, which can calm down excessive signaling in autoimmune and inflammatory diseases&lt;br /&gt;
&lt;br /&gt;
In short, 4F5W provides the structural foundation needed to understand, compare, and therapeutically target the STING pathway.&lt;br /&gt;
&lt;br /&gt;
== Structural highlights == Open dimer conformation (47–54 Å)&lt;br /&gt;
In the 4F5W apo structure, the two α2 helices are positioned far apart, creating a wide, open dimer.&lt;br /&gt;
This open arrangement corresponds to the inactive form of STING and matches the purple structure shown in your image.&lt;br /&gt;
&lt;br /&gt;
Ligand binding drives dimer closure (34–35 Å)&lt;br /&gt;
When a ligand such as cyclic-di-AMP binds, the dimer shifts into a much tighter, closed conformation.&lt;br /&gt;
The gold structure in your image clearly demonstrates this ligand-induced closing movement.&lt;br /&gt;
&lt;br /&gt;
C-terminal tail (CTT) is locked down in the apo state&lt;br /&gt;
In 4F5W, the C-terminal tail remains securely tucked into the protein.&lt;br /&gt;
This prevents:&lt;br /&gt;
&lt;br /&gt;
TBK1 from binding&lt;br /&gt;
&lt;br /&gt;
Any downstream signaling&lt;br /&gt;
&lt;br /&gt;
Any formation of STING polymers&lt;br /&gt;
&lt;br /&gt;
The polymerization interface is hidden&lt;br /&gt;
Because the CTT is still in place, the surface needed for polymer formation is not exposed in the apo structure.&lt;br /&gt;
Only after ligand binding—when the tail is released—does STING reveal this interface and form Cys148-linked polymers.&lt;br /&gt;
&lt;br /&gt;
Apo STING is unable to polymerize&lt;br /&gt;
Unlike ligand-bound structures (cGAMP- or CDA-bound STING), the apo 4F5W conformation cannot form linear polymers on the ER membrane.&lt;br /&gt;
This inability to polymerize explains why the apo form remains fully inactive.&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Disha Sonwani</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=File:4F5W.pse&amp;diff=4396738</id>
		<title>File:4F5W.pse</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=File:4F5W.pse&amp;diff=4396738"/>
		<updated>2025-11-30T17:21:54Z</updated>

		<summary type="html">&lt;p&gt;Disha Sonwani: uploaded a new version of &amp;quot;Image:4F5W.pse&amp;quot;: The 4F5W structure captures STING in its calm, inactive state. In this form, the protein sits as an open dimer, with the two arms of the molecule gently spread apart. Because no ligand is bound, STING isn’&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;The 4F5W structure captures STING in its calm, inactive state. In this form, the protein sits as an open dimer, with the two arms of the molecule gently spread apart. Because no ligand is bound, STING isn’t under any pressure to change shape—so it stays relaxed. The C-terminal tail remains neatly tucked away, almost like a safety lock that keeps the protein from accidentally activating.&lt;br /&gt;
&lt;br /&gt;
This structure represents STING exactly as it looks before sensing any danger, making it the perfect reference for understanding how the protein later closes, shifts, and comes alive when cGAMP or other ligands bind.&lt;/div&gt;</summary>
		<author><name>Disha Sonwani</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=File:4F5W.pse&amp;diff=4396733</id>
		<title>File:4F5W.pse</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=File:4F5W.pse&amp;diff=4396733"/>
		<updated>2025-11-30T17:20:09Z</updated>

		<summary type="html">&lt;p&gt;Disha Sonwani: The 4F5W structure captures STING in its calm, inactive state. In this form, the protein sits as an open dimer, with the two arms of the molecule gently spread apart. Because no ligand is bound, STING isn’t under any pressure to change shape—so it sta&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;The 4F5W structure captures STING in its calm, inactive state. In this form, the protein sits as an open dimer, with the two arms of the molecule gently spread apart. Because no ligand is bound, STING isn’t under any pressure to change shape—so it stays relaxed. The C-terminal tail remains neatly tucked away, almost like a safety lock that keeps the protein from accidentally activating.&lt;br /&gt;
&lt;br /&gt;
This structure represents STING exactly as it looks before sensing any danger, making it the perfect reference for understanding how the protein later closes, shifts, and comes alive when cGAMP or other ligands bind.&lt;/div&gt;</summary>
		<author><name>Disha Sonwani</name></author>
	</entry>
</feed>